Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
Bone Marrow Transplant
; 14(4): 635-6, 1994 Oct.
Article
em En
| MEDLINE
| ID: mdl-7858540
ABSTRACT
There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately severe VOD complicated by anuria following an allogeneic bone marrow transplant for relapsed acute myeloid leukaemia. Following initiation of peritoneal dialysis she received tPA at a dose of 10 mg/day for 5 days. There was rapid improvement in her urine output and liver function with no bleeding complications. This case suggests that the requirement of dialysis may not preclude the use of tPA in established VOD and therefore warrants further study.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Hepatopatia Veno-Oclusiva
/
Leucemia Mieloide Aguda
/
Transplante de Medula Óssea
/
Ativador de Plasminogênio Tecidual
Tipo de estudo:
Etiology_studies
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
1994
Tipo de documento:
Article